格隆汇2月18日｜莫德纳(MRNA.US)涨6.6%，美国食品药品监督管理局（FDA）启动对该公司流感疫苗 的审查。 ...

每经AI快讯，2月18日，莫德纳股价上涨6.6%。 （文章来源：每日经济新闻） ...

The Food and Drug Administration has reversed its decision not to review a new flu vaccine from Moderna, the pharmaceutical company said Wednesday.Last week, the FDA sent a missive to Moderna refusing to review its new shot, saying its application did not contain adequate research – leaving the company’s president Dr. Stephen Hoge in “complete shock.”Moderna’s flu vaccine will not be reviewed by the FDA. Rawf8 – stock.adobe.comIn an exclusive interview with The Post, Hoge said he was “completely surprised a ...

The U.S. Food and Drug Administration will review the investigational seasonal flu vaccine candidate after rejecting it earlier this month. ...

FDA reverses course and will review Moderna's mRNA flu vaccine, the company says https://t.co/jykQnuHtBx https://t.co/WOW8LeSJZS ...

FDA reverses course and will review Moderna's mRNA flu vaccine, the company says https://t.co/SpvmnBCYzC https://t.co/bYWc18XVQa ...

Group 1 - The company's mRNA flu shot, if approved, could be available for the 2026-27 flu season [1]

The US Food and Drug Administration will review a Moderna flu shot made with mRNA technology, reversing a previous decision that shocked Wall Street and spurred a public verbal dispute between the company and its regulator https://t.co/kO9TK4BTAK ...

A two-in-one mRNA vaccine developed by Moderna that targets seasonal influenza and COVID-19 produced robust and durable immune responses without safety concerns in a small mid-stage trial, the company... ...

Core Viewpoint - The U.S. Food and Drug Administration has accepted Moderna's application to review its influenza vaccine candidate [1] Company Summary - Moderna is advancing its influenza vaccine candidate through the regulatory process with the FDA's acceptance of its application [1]